Interaction study between enoxacin and fluvoxamine

Therapeutic Drug Monitoring

Volumn 27, Issue 3, 2005, Pages 349-353

  Kunii, Toshiki ^a   Fukasawa, Takashi ^a   Yasui Furukori, Norio ^b   Aoshima, Toshiaki ^a   Suzuki, Akihito ^a   Tateishi, Tomonori ^b   Inoue, Yoshimasa ^c   Otani, Koichi ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c Mitsubishi Pharma   (Japan)

Author keywords

CYP1A2; Enoxacin; Fluvoxamine; Interaction; Metabolism

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; ENOXACIN; FLUVOXAMINE; FLUVOXAMINE MALEATE; FLUVOXAMINO ACID; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SOMNOLENCE; STANFORD SLEEPINESS SCALE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ENOXACIN; FLUVOXAMINE; HUMANS; MALE;

EID: 20144362404     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000159134.94981.3f     Document Type: Article

References (24)

1. Wilde MI, Plosker GL, Benfield P. Fluvoxamine: an updated review of its pharmacology, and therapeutic use in depressive illness. Drugs. 1993;46:895-924.
2. Palmer KJ, Benfield P. Fluvoxamine: an overview of its pharmacological properties and review of its therapeutic potential in non-depressive disorders. CNS Drugs. 1994;1:57-87.
3. Perucca E, Gatti G, Spina E. Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1994;27:175-190.
4. Gertsenberg G, Aoshima T, Fukasawa T, et al. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology (Berl). 2003;167:443-448.
5. Carrillo JA, Dahl M-L, Svensson J-O, et al. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther. 1996;60:183-190.
6. Spigset O, Carleborg L, Hedenmalm K, et al. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther. 1995;58:399-403.
7. Bock KW, Shrenk D, Forster A, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics. 1994;4:209-218.
8. Spigset O, Granberg K, Hagg S, et al. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. Eur J Clin Pharmacol. 1997;52:129-133.
9. Fuhr U, Anders E-M, Mahr G, et al. Inhibitory potency of quinolone antibacterial agents against cytochrome P4501A2 activity in vitro and in vivo. Antimicrob Agents Chemother. 1992;36:942-948.
10. Harder S, Staib AH, Beer C, et al. 4-Quinolones inhibit biotransformation of caffeine. Eur J Clin Pharmacol. 1988;35:651-656.
11. Rogge MC, Solomon WR, Sedman AJ, et al. The theophylline-enoxacin interaction: 1. Effect of enoxacin dose size on theophylline disposition. Clin Pharmacol Ther. 1988;44:579-587.
12. Hoddes E, Zarcone V, Smythe H, et al. Quantification of sleepiness: a new approach. Psychophysiology. 1973;10:413-416.
13. Wechsler D. Wechsler Adult Intelligence Scale-Revised. New York: Harcourt Brace Jovanovich, 1981.
14. Lingjaerde O, Ahlfors UG, Beck P, et al. The UKU side effects rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 1987;76(Suppl 334).
15. Heim MH, Meyer UA. Genetic polymorphism of debrisoquine oxidation: restriction fragment analysis and allele-specific amplification of mutated alleles of CYP2D6. Methods Enzymol. 1991;206:173-183.
16. Johansson I, Oscarson M, Yue QY, et al. Genetic analysis of Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol. 1994;46:452-459.
17. Steen VM, Andreassen OA, Daly AK, et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics. 1995;5:215-223.
18. Yasui-Furukori N, Inoue Y, Kaneko S, et al. Determination of fluvoxamine and its metabolite fluvoxamino acid by liquid-liquid extraction and automated column-switching high-performance liquid chromatography. J Pharm Biomed Anal. 2005;7:37:121-125.
19. Rowland M, Tozer TN. Intergration with kinetics. In: Rowland M, Tozer TM, eds. Clinical Pharmacokinetics: Concept and Applications. 3rd ed. Baltimore: Williams & Wilkins, 1995, pp 184-200.
20. Spigset O, Axelsson S, Norstrom A, et al. The major fluvoxamine metabolite in urine is formed by CYP2D6. Eur J Clin Pharmacol. 2001; 57:653-658.
21. Gertsenberg G, Aoshima T, Fukasawa T, et al. Effects of the CYP2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Ther Drug Monit. 2003;25:463-468.
22. Di Nucci A, Candura SM, Tagliani M, et al. Fluoroquinolone-induced motor changes in the guinea-pig isolated ileum. Pharmacol Toxicol. 1998; 83:263-269.
23. Spigset O, Hagg S, Soderstrom E, et al. Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance. Eur J Clin Pharmacol. 1999;54:943-946.
24. Henwood JM, Monk JP. Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1988;36:32-66.